You are viewing the site in preview mode

Skip to main content

Table 6 Univariate analysis in the TCP-ALL patients

From: Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT

 

5 years

 

RI [95% CI]

NRM [95% CI]

LFS [95% CI]

OS [95% CI]

Year of AHSCT

 • 1999 - 2009

42.8% [37–48.5]

6.6% [4.1–9.9]

50.5% [44.5–56.2]

58.1% [52–63.7]

 • 2010 - 2020

36.1% [26–46.4]

10.2% [4.4–18.7]

53.7% [41.9–64.1]

56.7% [44.2–67.4]

P value

0.16

0.37

0.29

0.57

Patient age (years)

 • 18–32

39.8% [33.1–46.3]

5.3% [2.8–9]

54.9% [47.9–61.4]

61.4%[54.2–67.9]

 • 32+

42.6% [34.8–50.1]

9.7% [5.7–14.9]

47.7% [39.8–55.3]

54.4% [46.1–61.9]

P value

0.71

0.017

0.11

0.053

Patient sex

 • Male

42.1% [36.2–47.8]

6.2% [3.8–9.4]

51.7% [45.7–57.4]

59% [52.8–64.6]

 • Female

39% [28.8–49]

10.6% [5.1–18.4]

50.4% [39.3–60.4]

55.1% [43.5–65.2]

P value

0.35

0.43

0.52

0.76

Conditioning:

 • CT-based

41.7% [34.7–48.5]

10.3% [6.5–15.2]

48% [40.7–54.9]

53.8% [46.2–60.8]

 • TBI-based

40.4% [33.1–47.6]

3.8% [1.7–7.4]

55.7% [48–62.7]

63.1% [55.2–69.9]

P value

0.91

0.029

0.33

0.27

Time from diagnosis to AHSCT

 • <median

(6.6 months)

42.9% [35.8–49.8]

7.3% [4.2–11.6]

49.8% [42.5–56.7]

58.9%[51.4–65.7]

 • >=median

38.8% [31.7–45.8]

7.1% [3.9–11.6]

54.1% [46.5–61.1]

57.7% [49.7–64.8]

P value

0.52

0.98

0.55

0.88

Karnofsky score

 < 90

33.4% [17.1–50.6]

4.8%[0.3–20.4]

61.8% [41.2–77.1]

66.4% [44.8–81.2]

 >= 90

37.3% [28.7–45.8]

8.6% [4.5–14.5]

54.1% [44.7–62.5]

61% [51.1–69.5]

P value

0.68

0.26

0.32

0.47

  1. RI relapse incidence, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival, AHSCT autologous hematopoietic stem cell transplantation, ALL acute lymphoblastic leukemia, BCP-ALL B-cell precursor ALL, TCP-ALL T-cell precursor ALL, CT chemotherapy, TBI total body irradiation, CI confidence interval